Join Cerus for a non-CME Lunch Symposium at the SCA 39th Society of Cardiovascular Anesthesiologists (SCA) Annual Meeting and Workshops

TRANSFUSION SAFETY AND EFFICACY IN CARDIOVASCULAR SURGERY PATIENTS AND THE ROLE OF PATHOGEN REDUCED BLOOD COMPONENTS

LIMITED SEATING
RSVP AT HTTP://BIT.LY/2K8WWQN

CERUS’s Industry Sponsored Symposium is held for registered attendees of the 39th SCA Annual Meeting and Workshops (April 24-25, 2017 Orlando, FL). Funds for this program have been provided by a sponsorship fee from CERUS. This program is not associated with or part of the 39th SCA Annual Meeting and Workshops. *Clinicians licensed in a state where laws and regulations may prohibit accepting meals are welcome to attend and abstain from eating the provided lunch.
You’re Invited to Attend an Industry Education Workshop

MONDAY, APRIL 24, 2017 in OCEANA 7 from 12:30PM -1:30PM.

TRANSFUSION SAFETY AND EFFICACY IN CARDIOVASCULAR SURGERY PATIENTS AND THE ROLE OF PATHOGEN REDUCED BLOOD COMPONENTS

Over the past several years, blood management guidelines have emphasized the need for restrictive transfusion thresholds due to complications, such as the transmission of blood borne pathogens and infections. Yet, a significant portion of blood transfusions in the US are associated with cardiovascular surgery to correct perioperative anemia and coagulopathy. This symposium introduces the most recent US advancement in blood safety designed to mitigate transfusion-transmitted infections – pathogen reduced blood components. With pathogen reduced platelet and plasma components now FDA approved and available from several regional U.S. blood providers, the development of pathogen reduced red cell components is well underway. An overview will be provided on the clinical development program for the pathogen reduction of red cell components, including a planned US phase III trial that will evaluate the efficacy and safety of the INTERCEPT Blood System for Red Blood Cells in patients undergoing cardiac surgery procedures.

Speaker: Dr. Nina Mufti, Cerus Corporation